There has been continuing progress in measures to reduce the risk of transfusiontransmitted infection, including introduction of serologic tests of increased sensitivity and the recent implementation of investigational NAT in small pools of samples. STUDY DESIGN AND METHODS: Data relating to all blood donations to the American Red Cross have been consolidated into a single database. The prevalence of confirmed-positive test results for HBsAg, HCV, HIV, and HTLV were evaluated for each year for first-time donors from 1995 through 2001. Incidence rates for these infections were evaluated among repeat donors having at least two donations in a 2-year period. The frequencies of HIV-1 RNA-and HCV RNA-positive, seronegative donations were assessed for first-time and repeat donations. The relationship risk = (window period) × (incidence) was used to assess residual risk among repeat donations and to evaluate the incidence of HCV and HIV infection among first-time donors. RESULTS: During the study period, prevalence rates for all markers declined significantly over time: in 2001, the rates per 100,000 were 75.6 for HBsAg, 299 for HCV, 9.7 for HIV, and 9.6 for HTLV; the corresponding incidence rates (/100,000 person-years) were 1.267, 1.889, 1.554, and 0.239, respectively. Estimates of residual risk in donations from repeat donors (after NAT) for HCV and HIV were 1 per 1,935,000 and 1 per 2,135,000, respectively. However, incidence rates for these agents are approximately two times greater among first-time donors. For both HCV and HIV, NAT yield was concordant with that predicted by current window-period models. CONCLUSION: These data cover about half of all the whole blood collected in the United States. They suggest increasing improvement in transfusion safety and clearly define the benefit of pooled NAT.
S chreiber et al. 1 published a comprehensive assessment of the residual risk of transfusiontransmitted infection in 1996, using data collected from five blood centers from 1991 to 1993. Since that time, the sensitivity of serologic tests has improved, pooled NAT has been implemented, 2 and the prevalence and incidence of infectious disease markers has declined. [3] [4] [5] [6] [7] A number of publications have outlined these changes, but definitive, contemporary data are not available. We present data defining the incidence and prevalence of key infectious disease markers among voluntary donors to the American Red Cross from 1998 through 2001, and we use the method of Schreiber et al. 1 to define residual infection risk attributable to windowperiod infections. We consider the impact of pooled NAT for HIV-1 RNA and HCV RNA, using approaches based upon estimated window-period reduction and upon the actual yield of NAT.
MATERIALS AND METHODS
The analysis is based upon a comprehensive database representing all donations to the American Red Cross from 1995 to the present. The database includes test results on each donation linked to a unique identifier for the donor. For the purposes of this study, we reviewed data representing voluntary and directed donations of whole blood only. During the period covered by this study, all donations were tested using the following screening tests: HBsAg (ELISA System 2.0, Procedure B, Ortho Clinical Diagnostics, Raritan, NJ), anti-HCV (ELISA System 3.0, Ortho Clinical Diagnostics), anti-HIV-1/ HIV-2 (rDNA EIA Abbott Laboratories, Abbott Park, IL), and anti-HTLV I/II (Organon Teknika Vironostika HTLV I/II Microelisa System, bioMerieux, Durham, NC). Starting in February 1998, HIV-1 p24 antigen (HIV-1 p24 Antigen Elisa Test System, Coulter, Miami, FL) was begun.
Confirmatory and/or supplemental testing was performed on all repeatedly reactive samples using the following algorithms. Samples repeatedly reactive for HBsAg were tested by a second HBsAg EIA (Procedure C, Auszyme Monoclonal, Abbott Laboratories) and, if repeatedly reactive, were tested by a neutralization assay (HBsAg Confirmatory Assay, Abbott Laboratories). Samples repeatedly reactive for anti-HCV were further tested (HCV RIBA 3.0, Chiron, Emeryville, CA). Samples repeatedly reactive for anti-HIV-1 and/or anti-HIV-2 were confirmed by HIV-1 Western blot (Calypte Biomedical, Rockville, MD); HIV-2 confirmatory testing was also performed by EIA and Western blot (Bio-Rad, Redmond, WA). Anti-HTLV-I and/or -II repeatedly reactive samples were tested by a second ELISA (HTLV I/II, Abbott Laboratories), and samples repeatedly reactive in both ELISAs were evaluated by Western blot (Calypte Biomedical). As of April 29, 1999, the evaluative criteria for this Western blot were modified at the request of the FDA, requiring the presence of viral gag and env bands (excluding recombinant p21e) for a positive result. This led to a decline in the frequency of true-positive results. 8 Samples repeatedly reactive for HIV-1 p24 antigen were further evaluated by a neutralization assay (Coulter).
Starting in March 1999, all donations were evaluated by NAT in small pools (pools of 128 until September 1999 and pools of 16 thereafter) for HCV RNA and HIV-1 RNA by transcription-mediated amplification (Procleix HIV-1/ HCV Assay, Chiron). Algorithms used to deconstruct pools and to confirm the presence of HCV and/or HIV-1 RNA are described elsewhere. 2 This testing was performed under an Investigational New Drug application with FDA oversight.
To define the prevalence of infectious disease markers, the number of first-time donors was determined for each year from 1995 through 2001. For each marker, the numerator was the number of donations confirmed positive and the denominator was the total number of donations for which a test result (positive or negative) was available. To estimate the incidence of new infections, analyses were performed for successive, overlapping 2-year intervals from 1998 through 2001. Within each of these intervals, analyses were performed upon each donor who had at least one seronegative donation over the prior 2 years. For each marker analyzed, the numerator was the number of confirmed-positive test results. The denominator was calculated by summing the time intervals (in days) between the first and last donation for every donor. This denominator was converted to person-years, and incidence rates were expressed per 100,000 personyears.
The residual risk attributable to window-period donations was calculated by using the relationship risk = (window period) ‫ן‬ (incidence rate). For HBsAg, risk was calculated both with and without the adjustment described by Schreiber et al. 1 and Korelitz et al. 9 This adjustment involves multiplying the incidence rate by a correction factor to compensate for the transient expression of HBsAg in acute infections. We elected to use the 2.38 value reported by Schreiber et al. 1 because the assumptions underlying their estimate appear applicable to our own data. In addition, estimates of the incidence rate for HCV and HIV among first-time donors were developed by using a modification of the less-sensitive-test approach by Janssen et al., 10 but using the frequency of NATpositive results and published estimates of the duration of the NAT-only window. 1, 11 The incidence rate was derived from the relationship above by using the NAT-only window period and substituting the frequency of NATpositive results for "risk."
We have not presented 95-percent CIs for measures of incidence and prevalence because we are reporting observed data from the overall population of donations to the American Red Cross. Assessment of significance for trend was performed by chi-square test.
RESULTS
Measured prevalence rates for infectious disease markers among first-time donors are shown in Table 1 . The prevalence rates for all markers show a continuing pattern of decrease, which was highly significant for all markers, with chi-square values ranging from 45.2 to 711.7 (p < 0.001). It should be noted, however, that for HTLV, some component of this decrease is likely to be a result of a change in interpretive criteria for the Western blot in 1999, as described earlier. However, the trend was also significant for the period of 1995 through 1998 ( 2 = 4.135, p < 0.05). Measured incidence rates are shown in Table 2 . The incidence rates showed significant downward trends for HBsAg ( 2 = 6.613, p = 0.0101) and HTLV ( 2 = 40.2, p < 0.001). The HIV incidence rates have remained relatively constant over the overlapping 2-year periods. The rates for HCV have declined, but not significantly ( 2 = 2.497, p = 0.114). Residual risk estimates for window-period donations among repeat donors for the period of 2000 through 2001 were derived from these figures and from published estimates of window periods. 1 They are presented in Table 3 ; figures for 1998 through 1999 are also included for HTLV.
During the 3-year period starting in March of 1999, 19,811,809 donations were tested by NAT. Overall, five of these donations were seronegative but HIV-1 RNApositive, for a rate of 1 per 3.962 million, although one of these donations was also positive for HIV-1 p24 antigen. The corrected yield for HIV-1 RNA was therefore 1 per 4.953 million. The overall yield of HCV RNA-positive, seronegative donations was 74, for an overall rate of 1 per 267,700. Of the tested donations, 22.8 percent were from first-time donors. During this time, there were two HIV-1 RNA-positive, seronegative donations from first-time donors and three from repeat donors. Similarly, there were 34 HCV RNA-positive, seronegative donations from firsttime donors and 40 from repeat donors. These data permit additional questions to be explored.
First, is the yield of NAT consistent with predictions from the window-period model? If the incidence of HCV among repeat donors is 1.889 per 100,000 person-years and the detectable HCV RNA-positive window is 60 days, then it would be anticipated that, among the 15.295 million repeat donations tested, there would have been 47.5 NAT-positive donations whereas 40 were observed. This difference is not significant. Using the same approach with a 5-day HIV RNA window period and an incidence rate of 1.554 per 100,000 person-years, then 3.3 HIV RNApositive donations would have been anticipated; three were observed.
Second, what is the estimated incidence rate for HCV and HIV among first-time donors? For HCV, there were 34 HCV RNA-positive first-time donors among 4.52 million. Assuming an HCV RNA window of 60 days, then the calculated incidence rate is 4.58 per 100,000 person-years (95% CI, 3.17-6.40), or 2.42 times the rate among repeat donors. Similarly, calculations for HIV using a 5-day window period yield an incidence rate of 3.23 per 100,000 person-years (95% CI, 0.37-11.64), or 2.08 times the rate among repeat donors.
DISCUSSION
The data show a continuing downward trend in the prevalence of key infectious disease markers among presenting donors. This is consistent with a number of other publications. [3] [4] [5] [6] [7] While it is tempting to speculate about the reasons for this decline, it is not possible to identify any specific contributing factors. Incidence rates do not show such a clear trend: indeed, they have been stable for HIV and decreasing somewhat for HCV from 1999 through 2001. The rates for HBsAg have declined between 1999 and the present, although most of this change has been in the early part of the period. The clear decline in HTLV incidence is most likely due to reduced overall sensitivity attributable to the changed interpretive criteria.
As would be expected, point estimates of residual risk (i.e., the chance of collecting blood from a repeat donor during the window period) have declined materially since 1996, supporting the trends reported in more recent publications. The impact of NAT is most apparent in this respect, although it must be recognized that the projections in Table 3 are based upon a number of assumptions, including the length of the infectious window period itself and the length of the RNA-positive window. While we recognize the desirability of providing 95-percent CIs for risk estimates of this type, we do not believe that this is achievable with the available data. In particular, the major determinant of such CIs is the length of the window period. These were defined directly by Schreiber et al. 1 but have been successively modified by independent estimates of the impact of tests of increasing sensitivity, using unrelated samples. Thus, it does not appear possible to develop contemporary estimates of the variances of window periods. It is of interest to note that the actual yields of HCV NAT-and HIV NATpositive, seronegative donations do not differ significantly from those predicted on the basis of respective 60-and 5-day RNA window periods and the current measured incidence rates.
Janssen et al. 10 were able to measure incidence rates for HIV among first-time donors by using a less sensitive test method to identify those who were in the early stages of infection; this method was validated by its use among repeat donors with known incidence rates. Using an equivalent approach, we defined first-time donors with early infection as those who were positive only for HCV RNA or HIV RNA. Using existing estimates of the length of the RNA-only window period, we estimated incidence rates for these donors. Our data are consistent with the observation of Janssen et al. that HIV incidence rates are higher among first-time donors (albeit on a very small amount of data) and extend this observation to HCV, where we find that the incidence is about 2.4-fold higher among first-time donors, relative to repeat donors. 10, 11 Our results suggest that the risk of transmission of HIV or HCV from a blood unit is on the order of 1 in 2 million. This number is extremely low, but is not zero, and some potential infections have been reported after NAT (unpublished data). 12, 13 Risk has also declined for HBV and perhaps for HTLV, although there are many uncertainties in estimating risks for these agents. It is of interest that there are few, if any, reported transfusiontransmitted infections for these two agents. We recognize that we have only reported point estimates and that there is some uncertainty around these estimates. We consider, however, that the most important observation is the continuing decline of the estimated residual risk of transfusion-transmitted viral infection. The marginal benefits of further improvements in testing or of pathogen reduction are minuscule. Other risks of transfusion, including bacterial contamination of components, integrity of patient identification, and severe immunologic reactions deserve much more attention.
